Literature DB >> 7678065

Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation.

F G Schuening1, F R Appelbaum, H J Deeg, M Sullivan-Pepe, T C Graham, R Hackman, K M Zsebo, R Storb.   

Abstract

The effects of recombinant canine stem cell factor (rcSCF) on hematopoiesis were studied in normal dogs and in dogs given otherwise lethal total body irradiation (TBI) without marrow transplant. Results were compared with previous and concurrent data with recombinant granulocyte colony-stimulating factor (rG-CSF). Four normal dogs received 200 micrograms rcSCF per kilogram body weight daily either by continuous intravenous infusion for 28 days (n = 2) or by subcutaneous (SC) injection in two divided doses for 20 days (n = 2). All dogs showed at least a twofold increase in peripheral blood neutrophil counts starting approximately 7 days after the initiation of treatment. Hematocrit level and monocyte, lymphocyte, eosinophil, reticulocyte, and platelet counts were not elevated. Marrow sections after rcSCF treatment showed panhyperplasia. The only toxicity was facial edema during the first few days of rcSCF administration, presumably caused by mast cell stimulation. Ten dogs were given 400 cGy TBI at 10 cGy/min from two opposing 60Co sources. They were given no marrow infusion and received 200 micrograms/kg/d rcSCF SC in two divided doses for 21 days starting within 2 hours of TBI. Five of the 10 dogs showed complete and sustained hematopoietic recovery and survived as compared with 1 of 28 control dogs not receiving growth factor (P < .005). RcSCF treatment allowed for hematopoietic recovery in two of seven dogs administered 500 cGy of TBI but in none of five dogs given 600 cGy of TBI. Results with rcSCF are similar to those obtained with rG-CSF. The rate of neutrophil recovery in rcSCF-treated dogs after 400 cGy TBI was not different from that of rG-CSF-treated dogs (P = .65), but the rate of platelet recovery was faster (P = .06) in the rcSCF-treated animals. Combined treatment with rcSCF and rcG-CSF after 500 cGy TBI did not result in strongly improved survival as compared with results obtained with either factor alone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678065

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  An oral HemokineTM, α-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivo.

Authors:  Douglas V Faller; Serguei A Castaneda; Daohong Zhou; Merriline Vedamony; Peter E Newburger; Gary L White; Stanley Kosanke; P Artur Plett; Christie M Orschell; Michael S Boosalis; Susan P Perrine
Journal:  Blood Cells Mol Dis       Date:  2016-10-31       Impact factor: 3.039

2.  Impact of Abbreviated Filgrastim Schedule on Survival and Hematopoietic Recovery after Irradiation in Four Mouse Strains with Different Radiosensitivity.

Authors:  Merriline Satyamitra; Vidya P Kumar; Shukla Biswas; Lynnette Cary; Leonora Dickson; Srinivasan Venkataraman; Sanchita P Ghosh
Journal:  Radiat Res       Date:  2017-03-31       Impact factor: 2.841

3.  Lymphoid and Myeloid Recovery in Rhesus Macaques Following Total Body X-Irradiation.

Authors:  Ann M Farese; Kim G Hankey; Melanie Veirs Cohen; Thomas J MacVittie
Journal:  Health Phys       Date:  2015-11       Impact factor: 1.316

4.  Mitigation of ionizing radiation-induced bone marrow suppression by p38 inhibition and G-CSF administration.

Authors:  Deguan Li; Yueying Wang; Hongying Wu; Lu Lu; Heng Zhang; Jianhui Chang; Zhibin Zhai; Junling Zhang; Yong Wang; Daohong Zhou; Aimin Meng
Journal:  J Radiat Res       Date:  2011-10-05       Impact factor: 2.724

5.  5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.

Authors:  Andriyana K Bankova; Wendy W Pang; Brenda J Velasco; Janel R Long-Boyle; Judith A Shizuru
Journal:  Blood Adv       Date:  2021-10-12

6.  Total Body Irradiation in the "Hematopoietic" Dose Range Induces Substantial Intestinal Injury in Non-Human Primates.

Authors:  Junru Wang; Lijian Shao; Howard P Hendrickson; Liya Liu; Jianhui Chang; Yi Luo; John Seng; Mylene Pouliot; Simon Authier; Daohong Zhou; William Allaben; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2015-10-23       Impact factor: 2.841

Review 7.  Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes.

Authors:  J Grabbe; P Welker; E Dippel; B M Czarnetzki
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

8.  The ability of filgrastim to mitigate mortality following LD50/60 total-body irradiation is administration time-dependent.

Authors:  Ann M Farese; Cassandra R Brown; Cassandra P Smith; Allison M Gibbs; Barry P Katz; Cynthia S Johnson; Karl L Prado; Thomas J MacVittie
Journal:  Health Phys       Date:  2014-01       Impact factor: 1.316

9.  Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors.

Authors:  Hui Lin Chua; P Artur Plett; Carol H Sampson; Barry P Katz; Gilbert W Carnathan; Thomas J MacVittie; Keith Lenden; Christie M Orschell
Journal:  Health Phys       Date:  2014-01       Impact factor: 1.316

10.  Acute radiation syndrome (ARS) - treatment of the reduced host defense.

Authors:  Lars Heslet; Christiane Bay; Steen Nepper-Christensen
Journal:  Int J Gen Med       Date:  2012-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.